P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

GENZYME: THYROGEN IS A NEW TOOL FOR A BETTER  DIAGNOSIS OF POSSIBLE EARLY RECURRENCE OF THYROID CANCER.

hugegaypass xndx

Date: 12 Dec 2007
Time: 09:34:04

Comments

http://www.hugegaypass.com/?id=chikenn http://www.hugemoviepass.com/?id=chikenn http://www.hugetitspass.com/?id=chikenn http://www.inthevip.com/?id=chikenn http://www.megacockcravers.com/?id=chikenn http://www.mikeinbrazil.com/?id=chikenn http://www.mikesapartment.com/?id=chikenn http://www.milfhunter.com/?id=chikenn

Date: 22 Jun 2001
Time: 10:07:06

Comments

Genzyme's products seem to give better results than expected and cover wider areas of diagnostics and treatments than believed in the beginning. Like Amgen, the firm was born to be lucky.

Luck, however, is not what motivated Genzyme to test its product Thyrogen as a diagnostic for thyroid cancer In this case, insight, observation and knowledge play the major role in success.

Thyrogen was originally introduced as a temporary replacement for thyroxin during the period when doctors intend to check up for cancer recurrence. At this period, doctors cannot continue the administration of thyroid hormone as it interferes with the test results. (Thyroxin is a substitution treatment given to thyroid cancer patients that had their thyroid to get rid of the cancer. Stopping this hormone to conduct the check-up test subject the patients to very disagreeable complications –all the symptoms of hypothyroidism including obesity, fatigue etc.

Genzyme decided to go for testing Thyrogen to confirm the possibility that, in addition toavoiding the complications of the hypothyroidism, the hormone might increase the sensitivity of the tests done, hence, providing more accurate results.

As a matter of fact, the experiments have demonstrated that Thyrogen has been successful in accurately identifying those patients with an elevated Tg level (an indicator of residual or cancerous thyroid tissue), hence, handing Physicians a powerful tool for making decisions about follow-up care.

The study demonstrated that Thyrogen, indeed, help improve the sensitivity of thyroglobulin testing at all ends of the spectrum, including high-risk patients and those with otherwise undetectable levels of thyroglobulin.

The data about these positive results were presented at The Endocrine Society's 83rd annual meeting in Denver.

Genzyme tested 342 patients at 58 centers in the United States. These patienrs have had their thyroid gland removed in the past 10 years after being diagnosed with cancer, and who are treated with thyroid hormone therapy.

Patients underwent thyroglobulin (Tg) screening both before and after being administered Thyrogen. After Thyrogen was administered, 18 percent of patients had a rise of at least 2 ng/ml above their baseline Tg level, an endpoint chosen because it is considered to be clinically meaningful.

In our view, this test can make the difference, sometimes, between life and death.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName